Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease

This study has been completed.
Sponsor:
Information provided by:
PRAECIS Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT00100334
First received: December 29, 2004
Last updated: September 18, 2006
Last verified: September 2006

December 29, 2004
September 18, 2006
December 2004
Not Provided
Safety will be assessed through the occurrence of clinical adverse events and the occurrence of clinically significant changes from baseline.
Same as current
Complete list of historical versions of study NCT00100334 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease
Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease

This is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-moderate Alzheimer’s disease (AD). The primary objective of the study is to assess the safety of multiple IV injections of PPI-1019 in subjects with mild-moderate Alzheimer’s disease.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Alzheimer's Disease
Drug: PPI-1019 (APAN)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
August 2005
Not Provided

Inclusion Criteria:

  • Subject has the ability to understand the requirements of the study, provide written informed consent, and abide by the requirements of the study. In addition, a member of the subject’s family or a legally authorized representative must consent to the subject’s participation in the study.
  • Subject has a caregiver willing to assist the subject’s involvement in the study.
  • Subject is a male or female between the ages of 50 and 80 with a body mass index (BMI) below 31. Females must be post-menopausal at least 1 year or surgically sterilized.
  • Subject must have a cognitive deficit present for at least 1 year and meet DSM –IV criteria for Alzheimer’s disease and meet National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA) criteria for the presence of probable Alzheimer’s disease.
  • Subject’s severity of Alzheimer’s disease must be mild-moderate, documented with a Mini Mental State Exam (MMSE) score of 12-26.
  • Subject has a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within the prior 12 months which is compatible with a diagnosis of probable AD.
  • If a subject is being treated for Alzheimer’s disease, it must be with a single cholinesterase inhibitor (donepezil, rivastigmine, or galantamine), with or without memantine, and with a dose which has been stable for at least 3 months prior to dosing.
  • Subject performance status is ≤ 3 on items 1 through 5 and ≤ 2 on item 6 from the Degree of Disability Section of the “Rapid Disability Scale-2”
  • Subject agrees not to donate blood or blood products while participating in this study and for at least 60 days after discontinuing from the study.

Exclusion Criteria:

  • Subject has participated in a clinical trial of another investigational drug or device, or has taken any experimental drug within 30 days prior to admission to the Phase 1 unit. (Subjects previously enrolled in 1019-03-01 may be enrolled in 1019-04-01, only after a wash-out period of 45 days.)
  • Subject has a history compatible with vascular dementia as evidenced by a score of 5 or greater on the modified Hachinski Ischemia Scale.
  • Subject has evidence of clinically significant unstable cardiovascular, renal, hepatic, gastrointestinal, neurological, or metabolic disease within the past 6 months (as determined by medical history, ECG results, chest x-ray, or physical examination).
  • Subject performance status is > 3 on items 1 through 5 and > 2 on item 6 from the Degree of Disability Section of the “Rapid Disability Scale-2.”
  • Subject has diabetes that requires oral antidiabetic therapy or insulin.
  • Subject has a systolic blood pressure (sitting) of greater than 160 mmHg, a diastolic (sitting) greater than 95 mmHg, a decrease in systolic blood pressure of more than 30 mmHg upon standing for 2 minutes from a sitting or supine position, a pulse (sitting or supine) less than 50 or greater than 85.
  • Subject has any visual, hearing, or communication disabilities impairing his/her ability to participate in the study.
  • Subject is being treated with anticholinergics and/or clinically relevant cytochrome P450 3A4 inducers/inhibitors. The use of other concomitant medications for stable medical conditions is acceptable provided drug and dosage are stable for at least 4 weeks prior to dosing.
  • Subject is currently taking herbal supplements which interfere with drug metabolism, e.g. St. John’s wort, ginkgo biloba.
  • Subject has tested positive for drugs of abuse (amphetamines, barbiturates, cocaine, phencyclidine, or cannabinoids) on screening or Day -1
  • Subject has a current or past medical history of alcohol abuse.
  • Subject has any elevations (> 1.2 x ULN) on screening or Day -1 for ALT, AST, bilirubin, creatinine, blood urea nitrogen, or alkaline phosphatase.
  • Subject has any other screening or Day -1 laboratory values outside the normal ranges that are deemed clinically significant by the investigator.
Both
50 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00100334
1019-04-01
Not Provided
Not Provided
PRAECIS Pharmaceuticals Inc.
Not Provided
Not Provided
PRAECIS Pharmaceuticals Inc.
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP